Generic Name and Formulations:
Anidulafungin 50mg/vial, 100mg/vial; pwd for IV infusion after reconstitution and dilution; preservative-free; contains fructose and mannitol.
Indications for ERAXIS:
Candidemia. Esophageal candidiasis. Other Candida infections (intra-abdominal abscess, peritonitis).
Give by IV infusion; max rate 1.1mg/minute. Candidiasis, intra-abdominal abscess, peritonitis: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution.
≤16yrs: not established.
Follow-up if hepatic dysfunction develops. Discontinue and treat appropriately if anaphylactic reactions occur. Pregnancy: avoid. Nursing mothers.
Glucan synthesis inhibitor (echinocandin).
Hypokalemia, GI upset, pyrexia, insomnia, anemia, headache, dyspepsia; hepatic effects, infusion reactions, anaphylactic reactions.
Fecal, renal (minor).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline